LeadArt Biotechnologies Inc., a chemical proteomics specialist based in Ningbo, has reportedly raised close to USD 6 million in a Pre-Series A financing round. The funding was led by Bluerun Ventures, with participation from Yong Chao Venture Capital. The proceeds will be used for the development of a chemical proteomics automatic platform and the construction of the world’s largest human living cell level target probe binding database.
Company Background and Innovation
Founded in 2017, LeadArt Bio is known for its automation and digitalization-driven innovative drug discovery platforms. The company operates R&D centers in Ningbo and Chengdu, China, and Boston, Massachusetts, in the US. These platforms leverage advanced technologies to accelerate the discovery and development of novel drugs, positioning LeadArt Bio as a leader in the field of chemical proteomics.
Future Prospects and Strategic Use of Funds
The Pre-Series A funding round positions LeadArt Biotechnologies to further enhance its capabilities in chemical proteomics. By investing in the development of an automatic platform and expanding its target probe binding database, LeadArt Bio aims to solidify its position as a pioneering force in innovative drug discovery, addressing significant unmet medical needs globally.-Fineline Info & Tech
